Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499770 · ClinicalTrials.gov registry record · Phase 1
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
A Phase 1 study, sponsored by G1 Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT02499770 is a Phase 1 study that has completed, run by G1 Therapeutics. The registered enrollment target is 122 participants.
The verdict
NCT02499770, a Phase 1 study, has completed, sponsored by G1 Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 90 patients will be enrolled in the study; 20 patients in the Part 1 and 70 patients in the Part 2 portion.
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Etoposide
- DRUG Trilaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2015-06-26 |
| Est. Completion | 2019-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499770
The ClinicalTrials.gov registry entry for NCT02499770 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is G1 Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02499770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499770 about?
NCT02499770 is a clinical study titled "Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)". This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed exten...
What is the current status of trial NCT02499770?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2015-06-26. Estimated completion is 2019-02-22.
What interventions are being tested in trial NCT02499770?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Etoposide (DRUG), Trilaciclib (DRUG).
Who is sponsoring clinical trial NCT02499770?
This trial is sponsored by G1 Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.